Holen Sie sich die Stockscreener-App
46.15
0.17%
-0.08
Handel nachbörslich:
45.75
-0.40
-0.87%
Schlusskurs vom Vortag:
$46.23
Offen:
$46.66
24-Stunden-Volumen:
3.10M
Relative Volume:
1.41
Marktkapitalisierung:
$5.94B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-15.97
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
-4.37%
1M Leistung:
+46.74%
6M Leistung:
+39.76%
1J Leistung:
+2.58%
1-Tages-Spanne:
$45.75
$47.24
1-Wochen-Bereich:
$43.50
$48.10
52-Wochen-Spanne:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
46.15 | 5.95B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-06-11 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences Inc. Moves Into Overbought Range Analysts CautiousTrend Analysis for Safer Trades Gains Popularity - 선데이타임즈
Avidity Biosciences RNA 2025Q2 Earnings Preview Upside Potential on Novartis Acquisition Talks - AInvest
Avidity Biosciences' Promising Pipeline: Buy Rating Maintained by Ananda Ghosh - AInvest
Avidity Biosciences Bets Big On Rare Disease Therapies - Finimize
Avidity Biosciences Q2 Results: Analysts Boost Revenue Forecasts, Raise Loss Per Share Estimates - AInvest
The Avidity Biosciences, Inc. (NASDAQ:RNA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal - MSN
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $60 to $78 - 富途牛牛
Avidity (RNA) Gets 26% Jump on Potential Takeover - MSN
Chardan Capital Maintains "Buy" Rating for Avidity Biosciences with $75 Price Target - AInvest
Insider Selling at Avidity Biosciences: A Signal of Routine Tax Obligations or a Cause for Concern? - AInvest
Avidity Biosciences Insider Selling: Signal or Noise in a High-Potential Biotech Play? - AInvest
Avidity Biosciences Shares Slide 2.59% as 230M-Dollar Volume Ranks 431st Amid Analyst Optimism and Deepening Losses - AInvest
Avidity Biosciences Signs Manufacturing Agreement with Lonza - The Globe and Mail
Avidity Biosciences Insider Trading: Officers Buy and Sell Shares on 2025-08-06 - AInvest
Novartis weighs deal for biotech Avidity Biosciences, FT reports - AOL.com
Avidity Biosciences: Strong Buy Rating Backed by Promising Clinical Outcomes and Robust Financial Position - TipRanks
Avidity Biosciences: Wells Fargo maintains a 'Overweight' Rating, The Target Price is $75 - AInvest
Avidity Biosciences: Barclays Keeps Overweight Rating, Raises PT to $62 - AInvest
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $62 - 富途牛牛
Avidity Biosciences: Chardan Capital Maintains Buy, Raises PT to $75 - AInvest
Avidity Biosciences price target raised to $75 from $70 at Wells Fargo - TipRanks
Avidity Biosciences 2025 Q2 Earnings Significant Loss Widening Despite Revenue Surge - AInvest
Avidity (RNA) Q2 Revenue Jumps 88% - AOL.com
Avidity Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Avidity Biosciences Reports Q2 2025 Financial Results and Key Milestones, with Strong Cash Position and Upcoming FDA Submissions - AInvest
Avidity Biosciences: Promising Pipeline and Strategic Developments Drive Buy Rating Amid Potential Novartis Takeover Interest - AInvest
Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c) - TipRanks
Earnings Flash (RNA) Avidity Biosciences, Inc. Reports Q2 Revenue $3.8M - MarketScreener
Avidity Biosciences Secures FDA Breakthrough Status, Prepares for 3 Drug Launches Starting 2026 - Stock Titan
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium - MSN
Avidity Bio Climbs on Report of Novartis Takeover - MSN
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights07.08.25News - Ariva
Novartis eyes Avidity Biosciences in potential takeover: Report - Medical Dialogues
Rumour mill says Novartis may want to buy Avidity - pharmaphorum
Avidity Biosciences Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
Novartis's Strategic Pursuit of Avidity Biosciences: A Catalyst for Biotech Value and Long-Term Growth? - AInvest
Avidity Biosciences Surges 26% on 877% Volume Spike to 121st Most Traded as High-Volume Stocks Outperform with 166% Returns - AInvest
Novartis Eyes Avidity Biosciences Acquisition to Boost Rare Disease Pipeline - AInvest
Avidity Shares Surge 20% Following Report of Buyout Interest - AInvest
Avidity's Stock Jumps 3% Following Takeover Approach Report - AInvest
Avidity Biosciences Shares Surge Amid Novartis Acquisition Talks - AInvest
Novartis Makes Takeover Bid for Avidity Biosciences with $4.3B Market Value - AInvest
- Yahoo Finance
Biote Corp. shares fall 13.21% after-hours as Novartis considers Avidity Biosciences acquisition. - AInvest
Avidity Biosciences: What’s Fueling its Surge? - timothysykes.com
Small Biotech Catapults On Rumored Novartis Takeover - Investor's Business Daily
Biote Corp. shares fall 6.74% after-hours as Novartis considers Avidity Biosciences acquisition. - AInvest
Avidity Biosciences shares rise 24.05% intraday as Novartis considers a potential takeover offer. - AInvest
Celcuity Inc. shares rise 3.71% intraday as Novartis considers deal for biotech Avidity Biosciences. - AInvest
Avidity soars after rumours of Novartis' takeout interest emerge - FirstWord Pharma
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):